TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Peripheral Effects of Exercise on Cardiovascular Health (STRRIDE II)
Brief Summary: This study will investigate the separate and combined effects of aerobic and resistance training on cardiovascular risk factors in overweight men and women with mild to moderate dyslipidemia.


Options:
A: Arm Label: Resistance Training; Type: EXPERIMENTAL; Interventions: Behavioral: Resistance Training | Arm Label: Aerobic Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise | Arm Label: Combination RT & AT; Type: EXPERIMENTAL; Interventions: Behavioral: Combo | Arm Label: Control; Type: EXPERIMENTAL; Interventions: Behavioral: Continued Sedentary lifestyle | Intervention Type: BEHAVIORAL; Name: Resistance Training; Assigned to Arm(s): Resistance Training | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise; Assigned to Arm(s): Aerobic Exercise | Intervention Type: BEHAVIORAL; Name: Combo; Assigned to Arm(s): Combination RT & AT | Intervention Type: BEHAVIORAL; Name: Continued Sedentary lifestyle; Assigned to Arm(s): Control
B: Arm Label: HeartWare® VAS; Type: EXPERIMENTAL; Interventions: Device: HeartWare® VAS | Intervention Type: DEVICE; Name: HeartWare® VAS; Assigned to Arm(s): HeartWare® VAS
C: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training for 6 months | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training for 6 months; Assigned to Arm(s): Exercise training
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical training | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: No training | Intervention Type: BEHAVIORAL; Name: Physical training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: No training; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Trial of a Home-Based Peer Support Program After Coronary Artery Bypass Graft Surgery
Brief Summary: Coronary artery bypass graft (CABG) surgery is performed more frequently on individuals who are older and sicker than in previous years. Increased patient acuity and reduced hospital length of stays leave individuals ill prepared for their recovery following discharge. Individuals experience pain, functional impairment and depressive symptoms following discharge, which persist for 8 weeks in 50% of individuals. Unrelieved pain, functional decline and depressive symptoms predispose individuals to adverse events, impaired health-related quality of life (HRQOL), and increased morbidity and mortality.

Existing supports; including printed education materials, community care resources, cardiac rehabilitation programs and nurse-initiated telephone follow-up, fail to address concerns of individuals in this early period following hospital discharge.

Despite the positive health outcomes in other patient populations, valid studies examining the impact of telephone-based peer support to men and women after hospital discharge from CABG surgery were not found. It is anticipated that a home-based peer support program, delivered by telephone, will improve recovery and enhance HRQOL for individuals in the early weeks post hospital discharge from CABG surgery.


Options:
A: Intervention Type: OTHER; Name: Peer Support; Assigned to Arm(s): N/A
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Virtual Communities of practice | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Virtual Communities of practice; Assigned to Arm(s): Intervention group
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic Pill Bottle, Incentives, Social Influence | Intervention Type: BEHAVIORAL; Name: Electronic Pill Bottle, Incentives, Social Influence; Assigned to Arm(s): Intervention
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Healing Circles; Type: EXPERIMENTAL; Interventions: Behavioral: Healing Circles | Intervention Type: BEHAVIORAL; Name: Healing Circles; Assigned to Arm(s): Healing Circles

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Trial of a Home-Based Peer Support Program After Coronary Artery Bypass Graft Surgery
Brief Summary: Coronary artery bypass graft (CABG) surgery is performed more frequently on individuals who are older and sicker than in previous years. Increased patient acuity and reduced hospital length of stays leave individuals ill prepared for their recovery following discharge. Individuals experience pain, functional impairment and depressive symptoms following discharge, which persist for 8 weeks in 50% of individuals. Unrelieved pain, functional decline and depressive symptoms predispose individuals to adverse events, impaired health-related quality of life (HRQOL), and increased morbidity and mortality.

Existing supports; including printed education materials, community care resources, cardiac rehabilitation programs and nurse-initiated telephone follow-up, fail to address concerns of individuals in this early period following hospital discharge.

Despite the positive health outcomes in other patient populations, valid studies examining the impact of telephone-based peer support to men and women after hospital discharge from CABG surgery were not found. It is anticipated that a home-based peer support program, delivered by telephone, will improve recovery and enhance HRQOL for individuals in the early weeks post hospital discharge from CABG surgery.


Options:
A: Intervention Type: OTHER; Name: Peer Support; Assigned to Arm(s): N/A
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention Group | Intervention Type: BEHAVIORAL; Name: Intervention Group; Assigned to Arm(s): Intervention Group
C: Arm Label: conventional; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: structured; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education | Intervention Type: BEHAVIORAL; Name: education; Assigned to Arm(s): structured
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: education | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: education; Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of PONV by Acupressure. A Study of the Effect of a Recently Generated Danish Bracelet Vital-Band(R) Which Stimulates the Acupressure Point P6
Brief Summary: The purpose of this study is to determine whether stimulation to the akupressurpoint P6 with a recently developed bracelet are effective preventing postoperative nausea and vomiting


Options:
A: Intervention Type: DEVICE; Name: Acupressure; Assigned to Arm(s): N/A
B: Arm Label: Electroacupuncture; Type: EXPERIMENTAL; Interventions: Procedure: Electroacupuncture | Arm Label: Non-electroacupuncture; Type: SHAM_COMPARATOR; Interventions: Procedure: non-electroacupuncture | Intervention Type: PROCEDURE; Name: non-electroacupuncture; Assigned to Arm(s): Non-electroacupuncture | Intervention Type: PROCEDURE; Name: Electroacupuncture; Assigned to Arm(s): Electroacupuncture
C: Arm Label: Acustimulation; Type: EXPERIMENTAL; Interventions: Device: Acustimulation | Arm Label: Standard treatment group; Type: NO_INTERVENTION; Interventions: Device: Acustimulation | Intervention Type: DEVICE; Name: Acustimulation; Assigned to Arm(s): Acustimulation, Standard treatment group
D: Intervention Type: DEVICE; Name: Vital-band (R); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Study of Wide Excision Alone Versus Wide Excision With Intraoperative Lymphatic Mapping and Selective Lymph Node Dissection in the Treatment of Patients With Cutaneous Invasive Melanoma.
Brief Summary: Subjects must be diagnosed with melanoma. All subjects receive Wide Excision (WEX) of their melanoma. If the melanoma meets study requirements, the subject is randomized to receive either (1) no further surgical procedures as part of the study or (2) a Selective Lymphadenectomy with the possibility of a Complete Lymphadenectomy. Subjects are then followed for 10 years.


Options:
A: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
B: Arm Label: Dabrafenib and trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Dabrafenib and trametinib placebos; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib and trametinib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib and trametinib | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Dabrafenib and trametinib placebos
C: Arm Label: Dabrafenib plus Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vemurafenib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib plus Trametinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib plus Trametinib
D: Arm Label: WEX only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Wide Excision | Arm Label: WEX + SLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sentinel Lymph Node Dissection | Arm Label: WEX+SLND+CLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Complete Lymph Node Dissection | Intervention Type: PROCEDURE; Name: Sentinel Lymph Node Dissection; Assigned to Arm(s): WEX + SLND | Intervention Type: PROCEDURE; Name: Complete Lymph Node Dissection; Assigned to Arm(s): WEX+SLND+CLND | Intervention Type: PROCEDURE; Name: Wide Excision; Assigned to Arm(s): WEX only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Study of Wide Excision Alone Versus Wide Excision With Intraoperative Lymphatic Mapping and Selective Lymph Node Dissection in the Treatment of Patients With Cutaneous Invasive Melanoma.
Brief Summary: Subjects must be diagnosed with melanoma. All subjects receive Wide Excision (WEX) of their melanoma. If the melanoma meets study requirements, the subject is randomized to receive either (1) no further surgical procedures as part of the study or (2) a Selective Lymphadenectomy with the possibility of a Complete Lymphadenectomy. Subjects are then followed for 10 years.


Options:
A: Arm Label: RCM-OSS procedure; Type: EXPERIMENTAL; Interventions: Device: Reflectance confocal microscopy, Procedure: Surgical excision | Arm Label: Standard of care procedure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Punch biopsy, Procedure: Surgical excision | Intervention Type: DEVICE; Name: Reflectance confocal microscopy; Assigned to Arm(s): RCM-OSS procedure | Intervention Type: PROCEDURE; Name: Punch biopsy; Assigned to Arm(s): Standard of care procedure | Intervention Type: PROCEDURE; Name: Surgical excision; Assigned to Arm(s): RCM-OSS procedure, Standard of care procedure
B: Arm Label: WEX only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Wide Excision | Arm Label: WEX + SLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sentinel Lymph Node Dissection | Arm Label: WEX+SLND+CLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Complete Lymph Node Dissection | Intervention Type: PROCEDURE; Name: Sentinel Lymph Node Dissection; Assigned to Arm(s): WEX + SLND | Intervention Type: PROCEDURE; Name: Complete Lymph Node Dissection; Assigned to Arm(s): WEX+SLND+CLND | Intervention Type: PROCEDURE; Name: Wide Excision; Assigned to Arm(s): WEX only
C: Arm Label: Biopsied Pigmented Skin Lesions; Type: OTHER; Interventions: Device: MelaFind(R) | Intervention Type: DEVICE; Name: MelaFind(R); Assigned to Arm(s): Biopsied Pigmented Skin Lesions
D: Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Placebo + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Placebo | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab, Placebo + Ipilimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Ipilimumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Study of Wide Excision Alone Versus Wide Excision With Intraoperative Lymphatic Mapping and Selective Lymph Node Dissection in the Treatment of Patients With Cutaneous Invasive Melanoma.
Brief Summary: Subjects must be diagnosed with melanoma. All subjects receive Wide Excision (WEX) of their melanoma. If the melanoma meets study requirements, the subject is randomized to receive either (1) no further surgical procedures as part of the study or (2) a Selective Lymphadenectomy with the possibility of a Complete Lymphadenectomy. Subjects are then followed for 10 years.


Options:
A: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
B: Arm Label: observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: pegylated interferon alfa; Type: EXPERIMENTAL; Interventions: Biological: pegylated interferon alfa, Procedure: adjuvant therapy | Intervention Type: BIOLOGICAL; Name: pegylated interferon alfa; Assigned to Arm(s): pegylated interferon alfa | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): pegylated interferon alfa
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2
D: Arm Label: WEX only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Wide Excision | Arm Label: WEX + SLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sentinel Lymph Node Dissection | Arm Label: WEX+SLND+CLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Complete Lymph Node Dissection | Intervention Type: PROCEDURE; Name: Sentinel Lymph Node Dissection; Assigned to Arm(s): WEX + SLND | Intervention Type: PROCEDURE; Name: Complete Lymph Node Dissection; Assigned to Arm(s): WEX+SLND+CLND | Intervention Type: PROCEDURE; Name: Wide Excision; Assigned to Arm(s): WEX only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vulvar Vestibulitis Trial: Desipramine-Lidocaine
Brief Summary: The Vulvar Vestibulitis Clinical Trial (VVCT) a randomized, placebo-controlled, double blinded clinical trial. We will study the clinical efficacy of four medical treatments for vulvar vestibulitis: topical lidocaine, oral desipramine, combined lidocaine and desipramine, and placebo cream and capsules. Desipramine is a tricyclic antidepressant commonly used by clinicians for treatment of several chronic pain conditions that demonstrates an optimal side effect profile compared to other tricyclic antidepressants. Topical lidocaine has also been found to be beneficial for vulvar vestibulitis treatment in small studies. It is hypothesized that the combined use of oral desipramine and topical lidocaine will be more therapeutically effective than either one by itself and better than placebo.


Options:
A: Arm Label: Melatonin and Placebo; Type: EXPERIMENTAL; Interventions: Drug: Melatonin and Placebo | Arm Label: Amitriptyline and placebo; Type: EXPERIMENTAL; Interventions: Drug: Amitriptyline and Placebo | Arm Label: Melatonin and Amitriptylin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melatonin and Amitriptylin | Intervention Type: DRUG; Name: Melatonin and Placebo; Assigned to Arm(s): Melatonin and Placebo | Intervention Type: DRUG; Name: Amitriptyline and Placebo; Assigned to Arm(s): Amitriptyline and placebo | Intervention Type: DRUG; Name: Melatonin and Amitriptylin; Assigned to Arm(s): Melatonin and Amitriptylin
B: Intervention Type: DRUG; Name: duloxetine HCL; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: DVS SR Open Label; Type: OTHER; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): DVS SR Open Label
D: Intervention Type: DRUG; Name: topical lidocaine + oral desipramine, and/or placebo; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia
Brief Summary: The objectives of this study is:

* to establish the coverage rate of weekly iron supplementation in children in intervention schools over a period of nine months
* document any side effects of weeekly iron supplementation among children in intervention schools over a period of nine months asses the feasibility of incorporating the weekly iron supplementation programme into the normal school activity in intervention schools determine the extent of acceptability and support for the iron supplementation programme by staff at the health centre nearest to the intervention schools
* compare the praziquantel efficacy and schistosomiasis reinfection in children in intervention schools with that of children in control schools following the introduction of weekely iron supplementation over a period of nine months
* determine the impact of weekly iron supplementation on haemoglobin levels of children in intervention schools and compare with children in control schools over a period of nine months


Options:
A: Arm Label: Symptomatic malaria infection; Type: OTHER; Interventions: Dietary Supplement: Fe-57 orally, Fe-58 intravenously | Arm Label: Asymptomatic malaria infection; Type: OTHER; Interventions: Dietary Supplement: Fe-57 orally, Fe-58 intravenously | Arm Label: Hookworm infection; Type: OTHER; Interventions: Dietary Supplement: Fe-57 orally, Fe-58 intravenously | Arm Label: Schistosoma haematobium infection; Type: OTHER; Interventions: Dietary Supplement: Fe-57 orally, Fe-58 intravenously | Intervention Type: DIETARY_SUPPLEMENT; Name: Fe-57 orally, Fe-58 intravenously; Assigned to Arm(s): Asymptomatic malaria infection, Hookworm infection, Schistosoma haematobium infection, Symptomatic malaria infection
B: Arm Label: Vitamin/mineral fortificant with iron; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Sprinkles® | Arm Label: Vitamin/mineral fortificant without iron; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin/mineral fortificant without iron | Intervention Type: DIETARY_SUPPLEMENT; Name: Sprinkles®; Assigned to Arm(s): Vitamin/mineral fortificant with iron | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin/mineral fortificant without iron; Assigned to Arm(s): Vitamin/mineral fortificant without iron
C: Intervention Type: DRUG; Name: zinc sulphate dietary supplement; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iron sulphate-folic acid dietary supplement; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: ferrous sulphate (drug); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: A three year prospective, double blinded, placebo controlled, randomized clinical trial in impaired glucose tolerance (IGT) subjects to study the effect of pioglitazone in preventing the conversion to Diabetes.


Options:
A: Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone study drug, Drug: Pioglitazone Open Label | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Pioglitazone Open Label | Intervention Type: DRUG; Name: Pioglitazone study drug; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Pioglitazone Open Label; Assigned to Arm(s): Pioglitazone, Placebo
D: Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68); Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68); Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Liraglutide Placebo, no Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Liraglutide 3.0mg, Pre-diabetes; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide Placebo, Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), Liraglutide Placebo, no Pre-diabetes | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg, Pre-diabetes | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide Placebo, Pre-diabetes

Answer: A